Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
NERV Stock Summary
Top 10 Correlated ETFs
NERV
In the News
US FDA declines to approve Minerva Neurosciences' schizophrenia drug
Minerva Neurosciences said on Tuesday the U.S. Food and Drug Administration has declined to approve its experimental drug for the treatment of negative symptoms in patients with schizophrenia.
Minerva Neurosciences: There's Probably Time For One More Rally
Minerva Neurosciences has raised $20M through a private placement at a premium to market prices. Boehringer Ingelheim participated in the private placement. Boehringer is itself developing a drug for schizophrenia, albeit for cognitive impairments associated with schizophrenia. NERV has six months until the PDUFA goal date for its roluperidone application but used only $4M in cash in operating activities in Q2, so cash isn't currently a concern.
Here's Why Minerva Neurosciences (NERV) Is a Great 'Buy the Bottom' Stock Now
Minerva Neurosciences (NERV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Nasdaq ETF's First Six-week Rally Since Jan 2020: Stock Winners
Nasdaq ETF marked first six-week rally since Jan 2020. These stocks gained more than 100% during this time frame.
Minerva Neurosciences: Up About 250 Percent Since April With An FDA Catalyst Ahead
NERV has once again run on the submission of an NDA for roluperidone for the treatment of negative symptoms in schizophrenia. There will be no Refusal to File letter this time, with NERV using a dispute resolution process to its advantage.
What Makes Minerva Neurosciences (NERV) a New Buy Stock
Minerva Neurosciences (NERV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023
BURLINGTON, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release first quarter 2023 financial results and business updates on Monday, May 15, 2023.
Minerva Neurosciences, Inc. (NERV) Q4 2022 Earnings Call Transcript
Minerva Neurosciences, Inc. (NASDAQ:NERV ) Q4 2022 Earnings Conference Call March 8, 2023 8:30 AM ET Company Participants Geoff Race - President Remy Luthringer - CEO Fred Ahlholm - CFO Conference Call Participants Andrew Tsai - Jefferies Douglas Tsao - H.C. Wainwright Operator Good day, and thank you for standing by.
Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023
Management to Host Conference Call Management to Host Conference Call
Minerva (NERV) Down; FDA Denies Review Schizophrenia Drug NDA
Minerva (NERV) confirmed that the FDA's refuse-to-file letter on its regulatory filing, seeking approval for roluperidone, to treat symptoms of schizophrenia remains in effect.
NERV Financial details
NERV Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 8.07 | 0 | 0 | 0 | |
Net income per share | -14.8 | 0.38 | -9.35 | -7.3 | -4.61 | |
Operating cash flow per share | -8.91 | -6.63 | -4.61 | -4.62 | -2.27 | |
Free cash flow per share | -8.91 | -6.63 | -4.61 | -4.62 | -2.27 | |
Cash per share | 9.4 | 4.97 | 11.38 | 6.76 | 6.3 | |
Book value per share | 5.7 | 10.32 | 1.49 | -3.75 | -4.37 | |
Tangible book value per share | -0.47 | 4.43 | -1.3 | -6.54 | -6.66 | |
Share holders equity per share | 5.7 | 10.32 | 1.49 | -3.75 | -4.37 | |
Interest debt per share | 0.06 | 0.02 | 1.18 | 15.19 | 13.88 | |
Market cap | 277.39M | 95.53M | 34.23M | 8.49M | 40.01M | |
Enterprise value | 256.26M | 70.28M | -26.52M | 46.13M | 81.02M | |
P/E ratio | -3.84 | 49.22 | -0.69 | -0.22 | -1.33 | |
Price to sales ratio | 0 | 2.32 | 0 | 0 | 0 | |
POCF ratio | -6.39 | -2.82 | -1.39 | -0.34 | -2.71 | |
PFCF ratio | -6.39 | -2.82 | -1.39 | -0.34 | -2.71 | |
P/B Ratio | 9.99 | 1.81 | 4.29 | -0.42 | -1.41 | |
PTB ratio | 9.99 | 1.81 | 4.29 | -0.42 | -1.41 | |
EV to sales | 0 | 1.71 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -3.38 | 36.44 | 0.59 | -1.83 | -3.51 | |
EV to operating cash flow | -5.9 | -2.08 | 1.08 | -1.87 | -5.48 | |
EV to free cash flow | -5.9 | -2.08 | 1.08 | -1.87 | -5.48 | |
Earnings yield | -0.26 | 0.02 | -1.46 | -4.59 | -0.75 | |
Free cash flow yield | -0.16 | -0.35 | -0.72 | -2.9 | -0.37 | |
Debt to equity | 0.01 | 0 | 0 | -3.68 | -2.88 | |
Debt to assets | 0 | 0 | 0 | 1.34 | 1.44 | |
Net debt to EBITDA | 0.28 | -13.09 | 1.34 | -1.49 | -1.78 | |
Current ratio | 7.11 | 8.68 | 22.07 | 29.15 | 12.57 | |
Interest coverage | 0 | 0 | -7.17 | -3.41 | -2.79 | |
Income quality | 0.6 | -17.43 | 0.49 | 0.77 | 0.49 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0.42 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0.54 | 0 | 0 | 0 | |
Intangibles to total assets | 0.39 | 0.52 | 0.19 | 0.27 | 0.26 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | -1.92 | 0 | |
Stock based compensation to revenue | 0 | 0.24 | 0 | 0 | 0 | |
Graham number | 43.56 | 9.4 | 17.72 | 24.82 | 21.3 | |
ROIC | -2.6 | 0.04 | -5.49 | -0.57 | -0.43 | |
Return on tangible assets | -1.52 | 0.07 | -0.8 | -0.97 | -0.71 | |
Graham Net | -0.79 | 4 | -1.57 | -7.15 | -6.82 | |
Working capital | 40.51M | 24.28M | 59.38M | 38.78M | 38.66M | |
Tangible asset value | -2.29M | 22.59M | -6.94M | -34.94M | -43.34M | |
Net current asset value | -2.58M | 22.48M | -6.94M | -34.95M | -43.36M | |
Invested capital | 0.01 | 0 | 0 | -3.68 | -2.88 | |
Average receivables | 0 | 0 | 0 | 1.56M | 1.56M | |
Average payables | 2.06M | 1.66M | 1.42M | 1.41M | 1.39M | |
Average inventory | 0 | 0 | 0 | -1.51M | -1.51M | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 5.24K | 0 | 6.65K | 41.58K | 21.27K | |
Days of inventory on hand | 0 | 0 | 0 | -129.37K | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.07 | 0 | 0.05 | 0.01 | 0.02 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -2.6 | 0.04 | -6.26 | 1.95 | 1.05 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -1.57 | -0.67 | -1.12 | -1.03 | -1.19 | |
Operating cash flow per share | -0.77 | -0.02 | -0.7 | -0.91 | -0.79 | |
Free cash flow per share | -0.77 | -0.02 | -0.7 | -0.91 | -0.79 | |
Cash per share | 6.76 | 6.74 | 9.4 | 6.2 | 5.42 | |
Book value per share | -3.75 | -4.98 | -2.27 | -2.65 | -3.76 | |
Tangible book value per share | -6.54 | -7.78 | -4.97 | -4.62 | -5.73 | |
Share holders equity per share | -3.75 | -4.98 | -2.27 | -2.65 | -3.76 | |
Interest debt per share | 14.17 | 14.55 | 14.47 | 10.27 | 11.13 | |
Market cap | 8.49M | 8.54M | 50.37M | 52.23M | 46.55M | |
Enterprise value | 46.13M | 48.28M | 76.32M | 85.15M | 87.55M | |
P/E ratio | -0.25 | -0.59 | -2.03 | -1.67 | -1.29 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -2.07 | -74.04 | -13.01 | -7.57 | -7.77 | |
PFCF ratio | -2.06 | -74.04 | -13.01 | -7.57 | -7.77 | |
P/B Ratio | -0.42 | -0.32 | -4.03 | -2.61 | -1.64 | |
PTB ratio | -0.42 | -0.32 | -4.03 | -2.61 | -1.64 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -9.11 | -9.04 | -16.91 | -14.01 | -12.22 | |
EV to operating cash flow | -11.22 | -418.32 | -19.71 | -12.34 | -14.61 | |
EV to free cash flow | -11.22 | -418.32 | -19.71 | -12.34 | -14.61 | |
Earnings yield | -0.99 | -0.42 | -0.12 | -0.15 | -0.19 | |
Free cash flow yield | -0.48 | -0.01 | -0.08 | -0.13 | -0.13 | |
Debt to equity | -3.68 | -2.84 | -6.21 | -3.98 | -2.88 | |
Debt to assets | 1.34 | 1.47 | 1.16 | 1.26 | 1.44 | |
Net debt to EBITDA | -7.43 | -7.44 | -5.75 | -5.42 | -5.72 | |
Current ratio | 29.15 | 14.66 | 27.37 | 14.4 | 12.57 | |
Interest coverage | -2.63 | -2.7 | -2.23 | 2.92 | -3.27 | |
Income quality | 0.61 | 0.02 | 0.63 | 1 | 0.66 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.27 | 0.29 | 0.22 | 0.24 | 0.26 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.33 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 11.51 | 8.69 | 7.58 | 7.85 | 10.04 | |
ROIC | -0.12 | -0.17 | -0.09 | -0.1 | -0.05 | |
Return on tangible assets | -0.21 | -0.1 | -0.12 | -0.16 | -0.21 | |
Graham Net | -7.15 | -7.91 | -5.05 | -4.79 | -5.86 | |
Working capital | 38.78M | 34.17M | 50.32M | 44.88M | 38.66M | |
Tangible asset value | -34.94M | -41.52M | -27.41M | -34.92M | -43.34M | |
Net current asset value | -34.95M | -41.54M | -27.42M | -34.95M | -43.36M | |
Invested capital | -3.68 | -2.84 | -6.21 | -3.98 | -2.88 | |
Average receivables | 1.56M | 1.56M | 0 | 0 | 0 | |
Average payables | 751.28K | 965.33K | 629.62K | 846.66K | 1.6M | |
Average inventory | -1.51M | -1.51M | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 13.67K | 11.17K | 3.47K | 16.21K | 20.98K | |
Days of inventory on hand | -42.53K | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.01 | 0.01 | 0.03 | 0.01 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0.42 | 0.14 | 0.49 | 0.39 | 0.32 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
NERV Frequently Asked Questions
What is Minerva Neurosciences, Inc. stock symbol ?
Minerva Neurosciences, Inc. is a US stock , located in Waltham of Ma and trading under the symbol NERV
What is Minerva Neurosciences, Inc. stock quote today ?
Minerva Neurosciences, Inc. stock price is $2.58 today.
Is Minerva Neurosciences, Inc. stock public?
Yes, Minerva Neurosciences, Inc. is a publicly traded company.